Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Issue 4 (July 2015)

• Record Type: Journal Article
• Authors: Sato, Eri; Tanaka, Eiichi; Nakajima, Ayako; Inoue, Eisuke; Shimizu, Yoko; Yamaguchi, Rei; Ochiai, Moeko; Shidara, Kumi; Hoshi, Daisuke; Sugimoto, Naoki; Seto, Yohei; Taniguchi, Atsuo; Momohara, Shigeki; Yamanaka, Hisashi
• Is Part Of: Modern rheumatology. Volume 25:Issue 4(2015)
• Page Start: 528
• Page End: 533
• Publication Date: 2015-07
• Subjects: Rheumatology -- Periodicals; 616.723005
• DOI: 10.3109/14397595.2014.995892
• Languages: English
• ISSNs: 1439-7595

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objectives</italic>. To assess the effectiveness of the golimumab (GLM) 50-mg and 100-mg regimens in patients with rheumatoid arthritis (RA) in daily practice. <italic>Methods.</italic> We retrospectively analyzed RA patients who started GLM between September 2011 and July 2012. Patients were divided into three groups: a 50-mg group; a 50/100-mg group (had a dose increase to 100 mg); and a 100-mg group (started GLM at 100 mg). We assessed Disease Activity Score 28 (DAS28) and treatment continuation rate. Risk factors associated with time to discontinuation of the 50-mg regimen were determined with proportional hazards analysis. <italic>Results.</italic> We analyzed 74 patients: 43 in the 50-mg group, 23 in the 50/100-mg group, and 8 in the 100-mg group. DAS28 improved from 4.0 ± 1.0, 4.8 ± 1.0, and 4.7 ± 1.9, respectively, at baseline to 2.4 ± 1.2, 3.3 ± 1.5, and 2.5 ± 0.7, respectively, at week 52. Treatment continuation rates at week 52 were 73.7%, 60.9%, and 87.5%, respectively. In the 50/100-mg group, the mean DAS28 improved significantly from 4.4 ± 1.2 before to 3.6 ± 1.3 12 weeks after the dose increase. Oral corticosteroid therapy ≥ 5 mg/day, previous use of two biologic agents, and DAS28 &gt; 5.1 at initiation of GLM were significantly associated with discontinuation of the 50-mg regimen. <italic>Conclusions.</italic> Both GLM 50-mg and 100-mg regimens are effective in patients with RA in daily practice.</p> </abstract>